Jiangsu Recbio and Shanghai Rongsheng Collaborate on New Vaccine Development Project
Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. have recently announced a strategic cooperation for a groundbreaking new adjuvant vaccine research and development project in Shanghai. The partnership aims to revolutionize the creation of adjuvant vaccines through joint efforts.
The collaboration will leverage the strengths of both companies. Recbio will contribute its recently developed adjuvant from its adjuvant technology platform, while Rongsheng Biotech will provide its independently designed viral antigen. By integrating these advanced technologies, the initiative is set to enhance the immunogenicity of Rongsheng Biotech’s vaccines currently under development.
Dr. Liu Yong, the founder, chairman of the board, and general manager of Recbio, expressed his excitement about this important milestone for the application of Recbio’s adjuvant technology in supporting industry chain partners. He emphasized the crucial role of new adjuvants in the development and application of innovative vaccines.
Likewise, Zhu Shaorong, the founder and chairman of Rongsheng Biotech, highlighted the company’s significant achievements in technological innovation and successful research and development of various vaccine products. He also mentioned Rongsheng Biotech’s capacity for large-scale production.
This partnership between Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. represents a major step forward in the field of vaccine development. By combining their expertise, these two renowned companies are poised to make groundbreaking advancements in the creation and application of adjuvant vaccines.
Analyst comment
Positive news. The partnership between Jiangsu Recbio and Shanghai Rongsheng will revolutionize adjuvant vaccine development. By integrating their advanced technologies, the collaboration is expected to enhance the immunogenicity of Rongsheng Biotech’s vaccines. This partnership represents a major step forward in the field of vaccine development and will likely result in groundbreaking advancements.
